Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Express Scripts
Colorcon
AstraZeneca
Baxter

Last Updated: December 1, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for ANAVEX2-73


Email this page to a colleague

« Back to Dashboard

What is the drug development status for ANAVEX2-73?

ANAVEX2-73 is an investigational drug.

There have been 9 clinical trials for ANAVEX2-73. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2020.

The most common disease conditions in clinical trials are Alzheimer Disease, Syndrome, and Rett Syndrome. The leading clinical trial sponsors are Anavex Life Sciences Corp., Anavex Germany GmbH, and Anavex Australia Pty Ltd.

There are two US patents protecting this investigational drug and forty-seven international patents.

Recent Clinical Trials for ANAVEX2-73
TitleSponsorPhase
ANAVEX2-73 Study in Pediatric Patients With Rett SyndromeAnavex Australia Pty Ltd.Phase 2/Phase 3
ANAVEX2-73 Study in Pediatric Patients With Rett SyndromeAnavex Germany GmbHPhase 2/Phase 3
ANAVEX2-73 Study in Pediatric Patients With Rett SyndromeAnavex Life Sciences Corp.Phase 2/Phase 3

See all ANAVEX2-73 clinical trials

Clinical Trial Summary for ANAVEX2-73

Top disease conditions for ANAVEX2-73
Top clinical trial sponsors for ANAVEX2-73

See all ANAVEX2-73 clinical trials

US Patents for ANAVEX2-73

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ANAVEX2-73 ⤷  Try it Free Use of Sigma-1 receptor agonist compounds MTA Tamogatott Kutatocsoportok Irodaja (Budapest, HU) Semmelweis Egyetem (Budapest, HU) ⤷  Try it Free
ANAVEX2-73 ⤷  Try it Free Combination of 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1H)-yl]propoxy}benzamide and a NMDA receptor antagonist and pharmaceutical compositions containing the same Les Laboratoires Servier (Suresnes Cedex, FR) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Express Scripts
Colorcon
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.